Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALX Alexander's

Trading 05-18 11:17:35 EDT

236.14

+6.26

+2.72%

High236.14	Low227.11	Vol7.78K
Open227.11	D1 Closing229.88	Amplitude3.93%
Mkt Cap1.21B	Tradable Cap501.96M	Total Shares5.11M
T/O1.82M	T/O Rate0.37%	Tradable Shares2.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALX","market":"US","secType":"STK","nameCN":"Alexander's","latestPrice":236.14,"timestamp":1779117450137,"preClose":229.88,"halted":0,"volume":7778,"delay":0,"changeRate":0.027231599095180054,"floatShares":2125671,"shares":5107290,"eps":4.01,"marketStatus":"Trading","change":6.26,"latestTime":"05-18 11:17:35 EDT","open":227.11,"high":236.14,"low":227.11,"amount":1824201.8741199998,"amplitude":0.039281,"askPrice":236.97,"askSize":172,"bidPrice":234.65,"bidSize":3,"shortable":3,"etf":0,"ttmEps":4.01,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-7416000000,"exchange":"NYSE","adjPreClose":229.88,"dividendRate":0.076224,"preHourTrading":{"tag":"盘前","latestPrice":230.77,"preClose":229.88,"latestTime":"06:41 EDT","volume":10,"amount":2307.7000000000003,"timestamp":1779100905518,"change":0.89,"changeRate":0.003872,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":229.88,"preClose":229.88,"latestTime":"18:43 EDT","volume":5638,"amount":1296101.2,"timestamp":1778885031747,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.726681},"requestUrl":"/m/hq/s/ALX/tweets","defaultTab":"tweets","newsList":[{"id":"2636969018","title":"Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636969018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636969018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:40","pubTimestamp":1779036031,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-senti-biosciences-snti-alx-oncology-holdings-alxo-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-senti-biosciences-snti-alx-oncology-holdings-alxo-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","ALXO","HCSG","BK4505","LU0128526141.USD","XBI","BK4080","LU0320765992.SGD","SNTI","BK4139","IE0002141913.USD","IE00B2B36J28.USD","BK4137","XLV","ALX","BK4581","LU0889565916.HKD","ARGX","BK4585","LU0029874061.USD","IE00BFTCPJ56.SGD","LABU","LU1983260115.SGD","IE0034235188.USD","BK4539","IE00B4R5TH58.HKD","BK4231","LU0109394709.USD","IE0009355771.USD","LU2324357040.USD","IE00BJT1NW94.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634230733","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634230733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634230733?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:40","pubTimestamp":1778532009,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ALX Oncology Holdings (ALXO) and Heron Therapeutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-alx-oncology-holdings-alxo-and-heron-therapeutics-hrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-alx-oncology-holdings-alxo-and-heron-therapeutics-hrtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4080","BK4581","LU0128526141.USD","XLV","BK4231","LU0029874061.USD","ALXO","ALX","BK4137","HCSG","BK4588","BK4139","XBI","BK4585","HRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455131","title":"ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455131","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455131?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:02","pubTimestamp":1778241776,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 68.75 percent increase over losses of $(0.48) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52405396/alx-oncology-holdings-q1-adj-eps-0-15-beats-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455764","title":"ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455764","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455764?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:00","pubTimestamp":1778241600,"startTime":"0","endTime":"0","summary":"- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable resp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3291041/0/en/ALX-Oncology-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","ADC","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633443291","title":"ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression","url":"https://stock-news.laohu8.com/highlight/detail?id=2633443291","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633443291?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the ran","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289923/0/en/ALX-Oncology-s-Evorpacept-in-Combination-with-Zanidatamab-Generates-Promising-Durable-Response-in-Patients-with-Advanced-HER2-Positive-Breast-Cancer-and-High-CD47-Expression.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","BK4080","IE00B66KJ199.SGD","BK4157","AEIS","LU0757428866.USD","BK4231","IE0031619046.USD","LU1815336091.USD","IE00B7SZL793.SGD","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955972","title":"BRIEF-Alexander's Q1 Adjusted FFO Per Share USD 2.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955972","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955972?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:01","pubTimestamp":1777899669,"startTime":"0","endTime":"0","summary":"BRIEF-Alexander's Q1 Adjusted FFO Per Share USD 2.6\n\n\nMay 04 (Reuters) - Alexander's Q1 adjusted FFO USD 13.364 million.\n\nQ1 net income USD 4.662 million\nQ1 revenue USD 53.412 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXBC81F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632595557","title":"Alexander’s Announces First Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2632595557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632595557?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA4NGDBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4231","ALX","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955518","title":"Alexander's Q1 Adjusted Ffo per Share USD 2.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955518?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXBC81F1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4080","ALX","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955485","title":"Alexander's Q1 EPS USD 0.91","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955485?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXBC81F1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4080","ALX","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632555429","title":"Alexander's Q1 Adjusted Ffo USD 13.364 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632555429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632555429?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXBC81F1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4231","BK4080","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953251","title":"Earnings Flash (ALX) Alexander's Posts Q1 Non-GAAP FFO $2.60 a Share, vs. FactSet Est of $2.82","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953251?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:40","pubTimestamp":1777898453,"startTime":"0","endTime":"0","summary":"Earnings Flash (ALX) Alexander's Posts Q1 Non-GAAP FFO $2.60 a Share, vs. FactSet Est of $2.82","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALX.AU","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953905","title":"Alexander's Q1 FY26 net income drops to $4.66 million; revenue slips to $53.41 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953905?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:30","pubTimestamp":1777897826,"startTime":"0","endTime":"0","summary":"Alexander’s posted Q1 net income of $4.66 million, or $0.91 per diluted share, down from $12.31 million, or $2.40 per diluted share, a year earlier.Funds from operations fell to $13.36 million, or $2.60 per diluted share, from $20.84 million, or $4.06 per diluted share.Rental revenues slipped to $53.41 million from $54.92 million, pressured by lower rent from Home Depot’s lease expiration and other retail expirations at 731 Lexington Avenue.Operating expenses climbed to $28.98 million from $25.56 million, driven by higher recoverable costs including common area maintenance and real estate taxes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alexander's Inc. published the original content used to generate this news brief via EDGAR, the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbBgpH6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HD","LU1035775433.USD","LU1496350171.SGD","IE00BWXC8680.SGD","LU0820562030.AUD","LU1496350502.SGD","LU1929549753.HKD","BK4504","LU0823434583.USD","LU2461242641.AUD","IE00BKVL7J92.USD","LU2361045086.USD","LU0354030511.USD","LU0943347566.SGD","LU2361044865.SGD","LU1914381329.SGD","LU1778281490.HKD","LU1551013342.USD","LU1236620750.USD","IE00BZ1G4Q59.USD","LU0868494708.USD","LU0689472784.USD","LU2756315664.SGD","LU1551013425.SGD","LU2361044949.HKD","LU0820561909.HKD","BK4585","LU0823411888.USD","LU1069344957.HKD","LU1236620834.HKD","BK4231","BK4534","IE00B1XK9C88.USD","BK4588","LU0354030438.USD","BK4566","BK4080","LU1093756168.USD","LU1674673428.USD","LU1989772923.USD","ALX","BK4083","SG9999001440.SGD","LU0098860793.USD","LU0823434740.USD","LU0942090050.USD","LU0320765646.SGD","LU2756315318.SGD","BK4550","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632617829","title":"Alexander's Inc  expected to post  a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632617829","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632617829?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:13","pubTimestamp":1777641187,"startTime":"0","endTime":"0","summary":"Alexander's Inc  expected to post  a share - Earnings Preview Alexander's Inc ALX.N, ALX is expected to  show a fall in quarterly revenue when it reports  results on May 4 for the period ending March ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E0ZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4585","BK4588","BK4223","BK4080","ALX","VNO","BK4194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634990","title":"ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634990","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634990?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"ei=1758590&tp_key=2800839c82 Participant Listening Options by Phone: To access the conference call, please dial 1","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284796/0/en/ALX-Oncology-Announces-That-CD47-Biomarker-Data-from-Clinical-Trial-Evaluating-Evorpacept-Zanidatamab-Combination-in-Advanced-Breast-Cancer-Will-Be-Presented-at-ESMO-Breast-Cancer-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","IE00B19Z4B17.USD","LU1815336091.USD","IE00B7SZL793.SGD","ALX","LU0757428866.USD","IE0031619046.USD","IE00B66KJ199.SGD","BK4157","AEIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631754628","title":"Alexander's declares quarterly dividend of $4.5 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2631754628","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631754628?lang=en_us&edition=fundamental","pubTime":"2026-04-29 23:31","pubTimestamp":1777476686,"startTime":"0","endTime":"0","summary":"Alexander’s declared regular quarterly dividend of $4.5 per common share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLbt7B6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","BK4231","LU2095319765.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","ALX","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","BK4080","BK4588","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125481194","title":"Earning Preview: Alexander's Q1 revenue is expected to decrease by 3.06%, and institutional views are Neutral-to-Cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1125481194","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125481194?lang=en_us&edition=fundamental","pubTime":"2026-04-27 14:22","pubTimestamp":1777270965,"startTime":"0","endTime":"0","summary":"Abstract Alexander's will report its quarterly results on May 04, 2026 Pre-Market. This preview summarizes last quarter’s performance, outlines consensus expectations for revenue, margins, net...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Alexander's Q1 revenue is expected to decrease by 3.06%, and institutional views are Neutral-to-Cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629582760","title":"Alexander's publishes financial calendar update on upcoming quarterly results and call","url":"https://stock-news.laohu8.com/highlight/detail?id=2629582760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629582760?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:56","pubTimestamp":1776783400,"startTime":"0","endTime":"0","summary":"Alexander’s to release first-quarter earnings for period ended March 31, 2026 on May 4, 2026, before New York Stock Exchange open.Vornado Realty Trust to host quarterly earnings conference call on May 5, 2026 at 10:00 a.m. ET; discussion may include Alexander’s.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alexander's Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLb5Lltt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ALX","BK4194","BK4223","BK4231","BK4585","VNO","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628205781","title":"ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2628205781","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628205781?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:05","pubTimestamp":1776456300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April  17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/17/3276481/0/en/ALX-Oncology-Reports-Inducement-Grant-as-permitted-by-the-Nasdaq-Listing-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4231","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445945","title":"ALX Oncology Names Jeff Knight Chief Development, Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445945","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445945?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:17","pubTimestamp":1776089823,"startTime":"0","endTime":"0","summary":"ALX Oncology  said Monday it named Jeff Knight as chief development and operating officer, effective immediately.The company said Knight most recently served in the same role at Crinetics Pharmaceuticals .Shares of ALX were up over 8% in Monday trading.Price: 1.88, Change: +0.18, Percent Change: +10.59","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627458272","title":"Press Release: ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627458272","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627458272?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:30","pubTimestamp":1776083400,"startTime":"0","endTime":"0","summary":"- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution. SOUTH SAN FRANCISCO, Calif., April 13, 2026  -- ALX Oncology Holdings Inc. , a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced the appointment of Jeff Knight, M.P.H., as Chief Development and Operating Officer, effective April 13, 2026.\"Jeff is a highly accomplished leader with deep expertise across clinical development and operations, and a strong track record of both advancing innovative therapies through critical stages of growth and advancing companies of our stage through late-stage development and commercialization,\" said Jason Lettmann, Chief Executive Officer at ALX Oncology. \"We anticipate several important catalysts in the next 12 to 18 months with our evorpacept and ALX2004 clinical programs. Jeff's leadership will be instrume","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alx-inc.com","stockEarnings":[{"period":"1week","weight":-0.0655},{"period":"1month","weight":-0.0587},{"period":"3month","weight":-0.0171},{"period":"6month","weight":0.0617},{"period":"1year","weight":0.0416},{"period":"ytd","weight":0.0548}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alexander's, Inc. (NYSE: ALX) is a real estate investment trust (REIT), incorporated in Delaware, engaged in leasing, managing, developing and redeveloping its properties. All references to we, us, our, Company and Alexander's refer to Alexander's, Inc. and its consolidated subsidiaries. We are managed by, and our properties are leased and developed by, Vornado Realty Trust (Vornado) (NYSE: VNO). We have five properties in New York City.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01062},{"month":2,"riseRate":0.456522,"avgChangeRate":0.003648},{"month":3,"riseRate":0.521739,"avgChangeRate":0.01662},{"month":4,"riseRate":0.446809,"avgChangeRate":0.008427},{"month":5,"riseRate":0.510638,"avgChangeRate":0.022298},{"month":6,"riseRate":0.5,"avgChangeRate":0.00582},{"month":7,"riseRate":0.586957,"avgChangeRate":0.014946},{"month":8,"riseRate":0.478261,"avgChangeRate":0.005583},{"month":9,"riseRate":0.5,"avgChangeRate":0.023298},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013397},{"month":11,"riseRate":0.456522,"avgChangeRate":-0.006173},{"month":12,"riseRate":0.521739,"avgChangeRate":0.017167}],"exchange":"NYSE","name":"Alexander's","nameEN":"Alexander's"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alexander's(ALX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alexander's,ALX,Alexander's股票,Alexander's股票老虎,Alexander's股票老虎国际,Alexander's行情,Alexander's股票行情,Alexander's股价,Alexander's股市,Alexander's股票价格,Alexander's股票交易,Alexander's股票购买,Alexander's股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alexander's(ALX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alexander's(ALX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction